Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo Qvantig
nivolumab + hyaluronidase-nvhy · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Expands subcutaneous use to patients age 12 years or older weighing at least 30 kg for unresectable or metastatic melanoma alone or after IV nivolumab plus ipilimumab, and after complete resection of stage IIB, IIC, III, or IV melanoma.
LAMPGEN ANALYSIS
Why it matters
The action adds a subcutaneous option for eligible adolescents across advanced and adjuvant melanoma settings.
What research teams should watch
Document staging, resection and any IV induction treatment, then select the correct schedule and duration.
PRIMARY RECORDS